4 stories this morning, for surgeons and the people who support them.
- DePuy Synthes signs a U.S. sales agency agreement with SMAIO for the KEOPS-4ME planning platform and patient-specific K-ROD rods — Business Wire release datelined Dallas and Lyon, October 6, 2026 (reprinted in full by SPINEMarketGroup): SMAIO (Euronext Growth Paris, ALSMA) signed a sales agency agreement with DePuy Synthes (Raynham, MA), called a strategic collaboration. KEOPS-4ME combines data analysis, 3D planning via KEOPS Balance Analyzer 3D, and patient-specific K-ROD rods; SMAIO's planning/realignment solutions and patient-specific implants to be 'integrated directly' into DePuy's spine ecosystem, which the release names as VELYS Active Robotic Assistance and the TriALTIS pedicle screw system. No exclusivity, duration, territory beyond the U.S., or financial terms disclosed. SMAIO reports H1 2026 results and Q3 2026 revenue on October 13, 2026 after market close. Second sources: Becker's Spine Review ('DePuy Synthes inks spine surgery partnership', citing the Oct. 6 release), Zonebourse/Boursedirect and Ideal Investisseur (Oct 6, 2026). Prior KEOPS-4ME U.S. distribution deals: Highridge Medical (Business Wire, Sept 24, 2025, SMAIO's 'first major' one) and Orthofix (Business Wire, Oct 21, 2025). Competitive context: Medtronic UNiD patient-specific rods (from the 2020 Medicrea acquisition) were 510(k)-cleared for use with Medtronic's CD Horizon Solera, Voyager and Infinity OCT systems (OrthoWorld, MassDevice). No prior Morning Brief coverage of SMAIO, KEOPS, K-ROD or UNiD (grep of all drafts). Source
- FDA grants De Novo to Brixton Biosciences' ReneuRx (Neural Ice), an injectable cold slurry for knee OA pain, creating a new Class II category — FDA De Novo grant letter DEN250067, dated August 21, 2026 (read in full): ReneuRx (Neural Ice), Brixton Biosciences, correspondent MCRA; received Dec 15, 2025; new regulation 21 CFR 888.3048 'Injectable for thermal treatment of musculoskeletal pain', Class II, product code SJA, special controls, not 510(k)-exempt (followers must file a 510(k)). Indication: 'intended for pain management by inhibiting nerve signaling through the introduction of a multiphase suspension into the extraneural space of the target sensory nerve. The device is indicated for the management of knee pain in adults with symptomatic osteoarthritis (OA).' Special controls require clinical testing against a clinically justified comparator and labeling with clinical data summary and its limitations. Second source: Orthopedics This Week, 'Putting Pain on Ice: FDA Opens a New Chapter in Injectable Nerve Treatment', Oct 9, 2026 (orthotw.com), same decision date and regulation. Brixton's own Aug 18, 2026 Business Wire release (Yahoo Finance reprint) said a De Novo had been submitted on a head-to-head pivotal trial against a steroid injection, decision expected by end of 2026, data to be presented at a medical meeting later this year; no Brixton announcement of the grant found. ClinicalTrials.gov API (NCT06700109, ICE study, Brixton): injections around superolateral, superomedial and inferomedial genicular nerves vs single 40 mg intra-articular triamcinolone; primary endpoint proportion with >=30% NRS reduction in post-activity (Timed Up and Go) knee pain at 3 months; enrollment 263 (listed as estimated); active, not recruiting; estimated completion Feb 1, 2027; no results posted. Pacira iovera cryoneurolysis cleared for knee OA pain since 2017 (probe/needle-based). No prior Morning Brief coverage of Brixton, ReneuRx, Neural Ice or iovera (grep). Source
- Anesthesia & Analgesia RCT, 180 PLIF patients: deep neuromuscular block cut 3-month chronic postsurgical pain from 34.8% to 19.1% versus moderate block; no significant difference at 6 months — Wang X, Xia J, Huang D, ... Liu S. Anesth Analg, 2026 Oct 7, doi 10.1213/ANE.0000000000008324, PMID 42848950. Verified against the PubMed abstract via NCBI E-utilities. Affiliated Hospital of Xuzhou Medical University and two other Xuzhou hospitals, China. Patients scheduled for posterior lumbar interbody fusion randomized to deep (DNMB) vs moderate (MNMB) neuromuscular blockade; 180 randomized, 178 in modified ITT. Primary: CPSP incidence at 3 months, 17/89 (19.1%) vs 31/89 (34.8%), RR 0.6 (95% CI 0.3-0.9), P=.018. 6 months: 13/89 (14.6%) vs 17/89 (19.1%), RR 0.8 (0.4-1.5), P=.423. DNMB: lower postoperative pain scores, lower opioid consumption, higher surgeon satisfaction; lower CK, myoglobin and LDH on POD1 (all P<.001); better preserved paraspinal cross-sectional area and less fat infiltration progression on 6-month MRI (all P<.001). Abstract does not state reversal agent or block depth targets, so the script does not either. No prior Morning Brief coverage (grep neuromuscular, sugammadex). Source
- J Neurosurg Spine, CSM-Protect secondary analysis: dysphagia after multilevel anterior surgery for cervical myelopathy peaked at 68.6% and was still 36.4% at one year — Bak AB, Pedro KM, Moghaddamjou A, Fehlings MG; CSM-Protect Study Group. J Neurosurg Spine, 2026 Oct 9:1-6, doi 10.3171/2026.4.SPINE26260, PMID 42854252. Verified against the PubMed abstract via NCBI E-utilities. Retrospective review of patients prospectively enrolled in the phase III CSM-Protect trial (the riluzole-vs-placebo DCM decompression trial, Lancet Neurol 2021, PMID 33357512) who had anterior decompression 2012-2017; 132 of 290 eligible. Bazaz scale at baseline, 35, 180 and 365 days. Baseline moderate dysphagia 11.4%. Dysphagia 68.6% at 35 days (14% severe), 47% at 180 days, 36.4% at 365 days; at 1 year 10.6% moderate and 3.0% severe. Multivariable (adjusting for randomization and site): surgery at C5 OR 4.52 (95% CI 1.16-19.4), baseline dysphagia OR 4.56 (1.74-12.9), shorter myelopathic symptom duration OR 0.98 per month. Cohort described as primarily multilevel. No prior Morning Brief coverage (grep CSM-Protect, dysphagia). Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.